536-46-9

应用筛选条件

关键词:'536-46-9'

显示 1-1 共 1 条结果关于 "536-46-9" 范围论文

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

Hertzel C Gerstein et al.

Lancet (London, England), 394(10193), 121-130 (2019-06-14)

Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk with high glycated haemoglobin A1c (HbA1c) concentrations. We assessed the effect of the GLP-1 receptor agonist dulaglutide on major adverse

1/1